Value Analysis Committee Guide for Medical Device Vendors
Value analysis committees control product access at most hospitals. This guide explains how they work and how vendors can prepare winning submissions.
Updated February 2026
What Value Analysis Committees Are and Why They Matter
If you sell products into hospitals — medical devices, clinical supplies, implants, capital equipment, or even some software — you will eventually face a value analysis committee (VAC). These committees exist at the vast majority of U.S. hospitals and health systems, and they serve as the formal gatekeeping body for new product introductions, product conversions, and contract renewals.
A VAC is not a purchasing committee. Purchasing (or procurement/supply chain) executes buying decisions. The VAC evaluates whether a product should be approved for use in the first place. It assesses clinical value, financial impact, safety, and operational fit. Only after the VAC approves a product does it move to contract negotiation and purchasing. This distinction matters because many vendors prepare financial proposals when the VAC wants clinical evidence, or they pitch features when the committee needs a total cost of ownership analysis.
Why hospitals use value analysis. Physician-preferred items (PPIs) — products that specific physicians request based on their training and experience — account for an estimated 40-60% of a hospital's total supply costs, according to research published by the Association for Health Care Resource & Materials Management (AHRMM). Left unchecked, individual physician preferences can create a situation where a hospital stocks five different brands of the same implant at different price points with different inventory requirements. VACs exist to impose discipline on this process: standardize where possible, justify exceptions where necessary, and ensure every product entering the hospital delivers value relative to its cost.
The stakes are high for vendors. A VAC approval opens the door to the entire facility or health system. A VAC rejection can lock you out for 12-24 months until the next review cycle. And the process itself is opaque to many vendors — committees meet monthly or quarterly, the submission requirements vary by institution, and the decision criteria are not always published. Understanding how VACs work is a prerequisite for selling into hospitals effectively.
This guide provides a practical, vendor-facing walkthrough of the value analysis process: who sits on the committee, how submissions are evaluated, how to build a financial case, and how to identify and equip a clinical champion inside the hospital.
VAC Composition: Who Sits on the Committee
Value analysis committees vary in size and structure, but most include representatives from five functional areas. Understanding who's in the room — and what each person cares about — determines how you frame your submission.
Supply chain / materials management. The supply chain director or manager is typically the VAC chair or co-chair. This person manages the submission process, coordinates meetings, and ensures that product evaluations follow a consistent methodology. Their primary concerns are cost, contract terms, inventory impact, and standardization. They evaluate your product against what's currently on contract and what GPO pricing is available. Come prepared with pricing comparisons, GPO contract references, and inventory management details (shelf life, storage requirements, par levels).
Clinical leadership. This includes OR directors, nursing leadership, department managers, and clinical specialists relevant to the product category. A surgical product submission will involve OR leadership; a wound care product will involve wound care nurses. These members evaluate clinical efficacy, ease of use, patient outcomes, and staff training requirements. They want to see clinical evidence — peer-reviewed studies, FDA clearance details, outcomes data from comparable institutions. Anecdotal claims don't survive this group.
Physicians. Many VACs include one or more physicians, often the medical director, chief of surgery, or specialty-specific department chiefs. Physician participation varies — some VACs have highly engaged physician members, others have physicians who attend intermittently. When physicians are present, they focus on clinical outcomes, procedural efficiency, and how the product compares to what they've used at other institutions. A physician member who supports your product is your strongest asset.
Finance. A representative from the finance department — often a financial analyst or the CFO's delegate — evaluates the total cost of ownership. Not just unit price, but implementation costs, training costs, projected utilization, reimbursement impact, and effect on case margins. Finance members ask questions like: "If we switch to this product, what happens to our DRG reimbursement?" and "What's the payback period on this capital investment?" Come with financial models, not just pricing sheets.
Quality and risk management. Some VACs include quality officers or risk management representatives who assess safety data, recall history, FDA warning letters, and liability considerations. For implantable devices, this scrutiny is intense. Have your safety data organized: adverse event reports, post-market surveillance data, and any relevant FDA documentation.
Infection prevention, pharmacy, and IT. Depending on the product, additional stakeholders may join. Drug-eluting devices involve pharmacy. Connected devices involve IT/biomed. Products with sterilization requirements involve infection prevention. Ask the supply chain contact who will be reviewing your submission so you can prepare materials for each stakeholder.
The Value Analysis Process: Six Steps From Submission to Decision
While every hospital's process has nuances, most VAC evaluations follow a six-step sequence. Understanding this sequence lets you prepare the right materials at the right time.
Step 1: Product request initiation. Someone inside the hospital — usually a physician or department head — requests that a new product be evaluated. This is the trigger. Without an internal request, most VACs will not review a product submitted by a vendor directly. Your first job as a vendor is not to submit to the VAC yourself — it's to get a clinician inside the hospital to submit the request on your behalf. This is why the clinical champion (discussed in the next section) is so important.
Step 2: Submission package preparation. The requesting clinician and the vendor together prepare a submission package. This typically includes: product description and specifications, clinical evidence (studies, outcomes data), pricing and cost comparison vs. current product, FDA clearance documentation, vendor information (company background, support capabilities), and a clinical rationale for why the product is needed. Many hospitals have a standardized submission form — ask the supply chain department for it.
Step 3: Preliminary review. The supply chain team and a subset of the VAC conduct a preliminary review. They check whether the product duplicates something already on contract, whether GPO pricing is available, whether clinical evidence meets the committee's standards, and whether the financial case is complete. Incomplete submissions get sent back — this is where many vendor submissions stall. Make sure every field is filled, every question is answered, and every document is attached before the first review.
Step 4: Clinical evaluation / trial. If the submission passes preliminary review, the VAC may approve a clinical trial or evaluation period. For devices, this might be a 30-90 day trial in the OR or clinical setting. For supplies, it might be a unit-by-unit comparison. The trial generates real-world feedback from the clinicians who will use the product. As a vendor, your job during the trial is to provide flawless support — in-service training, on-site representation during first cases, responsive technical support, and proactive check-ins with users.
Step 5: Committee review and vote. After the trial (or based on the submission alone for some product categories), the full VAC reviews the evidence and votes. Some committees use a simple majority; others require consensus. The vote considers clinical evidence, trial feedback, financial analysis, and strategic fit. This meeting is where your champion presents the case internally. You likely won't be in the room.
Step 6: Decision and implementation. The VAC issues one of three decisions: approved, approved with conditions (e.g., limited to specific departments or a trial period), or denied. If approved, the product moves to contract negotiation with supply chain and, if applicable, GPO channel procurement. Implementation timelines vary — a simple supply conversion might happen in weeks, while a capital equipment installation takes months.
Building the Financial Case Using Hospital-Specific Data
The financial case is where most vendor submissions are weakest. Generic ROI calculators with national average assumptions don't persuade a committee that reviews dozens of vendor pitches per year. What works is a financial case built on the hospital's own data — or on data specific enough to the hospital's situation that the committee trusts the numbers.
Start with the hospital's current costs. Before you can show savings or value, you need to establish the baseline. What does the hospital currently spend on the product category you're addressing? If you can get this from your champion, ideal. If not, estimate it using publicly available data: CMS cost reports provide departmental spending data for Medicare-certified hospitals. You can access these through the CMS data portal. Combine with case volume data (also available from CMS) to estimate per-case costs.
Frame the financial impact in terms the CFO understands. Don't just show a lower unit price. Show the total cost of ownership, which includes: unit cost multiplied by projected annual volume, implementation and training costs (one-time), inventory carrying costs (how much do they need to stock?), service and maintenance costs (for capital equipment), and any revenue or reimbursement impact. A product that costs 10% more per unit but reduces complications (and therefore readmissions, which Medicare penalizes) can have a net positive financial impact. Build that story with numbers.
Use peer benchmarking. Hospitals are heavily influenced by what comparable institutions do. If you can show that hospitals of similar size, type, and geography have adopted your product and achieved measurable results, that's powerful evidence. "Six of the eight level-II trauma centers in the Southeast have adopted this system, with an average 12% reduction in OR turnaround time" is more compelling than "our customers see great results." Provider data lets you identify peer institutions and build these comparisons objectively.
Address the implementation cost honestly. VACs are skeptical of financial projections that show savings from day one. Switching products costs money — staff training, workflow disruption, potential learning curve effects on outcomes and efficiency. Acknowledge these costs in your financial model. Show a realistic timeline: implementation costs in months 1-3, break-even by month 6, net savings starting month 7. Committees trust vendors who present honest numbers more than those who present utopian projections.
Prepare for the "do nothing" comparison. The default option for any VAC is to keep the current product. Your financial case must be compelling relative to the status quo, not just relative to other alternatives. If switching saves $50,000 per year but costs $100,000 to implement, the payback period is two years — and the committee needs to believe you'll still be around in two years. Include references, case studies, and financial stability indicators for your company.
Identifying and Equipping the VAC Champion
No vendor wins a VAC approval alone. The most important factor in a successful value analysis submission is having a credible, motivated champion inside the hospital. This person — almost always a physician or senior clinician — submits the product request, presents the case to the committee, answers clinical questions, and advocates for approval during deliberation.
Who makes a good champion? The ideal VAC champion has three qualities: clinical credibility (the committee respects their judgment), direct experience with your product (they've used it at another institution, during a fellowship, or in a trial), and enough institutional influence to carry a vote. Department chairs, division chiefs, and medical directors are obvious choices. But a well-respected mid-career surgeon who consistently participates in committees can be equally effective. What doesn't work: a new physician who hasn't built trust yet, or a physician who champions every new product (the committee learns to discount their enthusiasm).
How to identify potential champions. Look at physician backgrounds using provider data and public sources. Where did they do residency and fellowship? (They may have used your product during training.) Where did they work before this institution? (They may have used your product at a previous employer.) What clinical interests or publications do they have? (Physicians who publish on a topic related to your product are natural champions because they have academic credibility on the subject.) What committee assignments do they hold? (A physician who already sits on the VAC is an obvious target, but even membership on quality or safety committees suggests engagement with institutional improvement.)
What your champion needs from you. Don't just ask a physician to champion your product — equip them. Provide a pre-filled submission form (they can modify it, but don't make them start from scratch). Give them a clinical evidence summary organized by the outcomes the VAC cares about: safety, efficacy, cost-effectiveness, and patient satisfaction. Prepare a financial summary they can present with confidence. Offer to do an in-service or lunch-and-learn with the clinical team so that when the trial happens, the staff is prepared. Your champion is investing their reputation and time — make sure they feel supported.
Avoid the common mistake: going around the champion. Some vendors try to lobby multiple VAC members directly, bypassing their champion. This backfires. Committee members notice when a vendor contacts them independently, and it can undermine your champion's credibility ("if the product is so good, why is the vendor doing their own lobbying?"). Work through your champion. If the champion needs help reaching a specific committee member, ask them to make the introduction. Keep the champion in control of the internal process.
When the champion isn't enough. Sometimes even a strong champion loses the vote — pricing, contract timing, or institutional politics can override clinical preference. In that case, maintain the relationship, document the feedback, and prepare for the next cycle. VAC decisions are revisited periodically, and a product that was denied this year may be approved next year if you address the committee's concerns.
Benchmarking Against Peer Institutions
Hospitals are inherently comparative organizations. They benchmark clinical outcomes, financial performance, patient satisfaction, and staffing ratios against peer institutions. Value analysis committees apply this same comparative mindset to product decisions. Showing that comparable hospitals use your product — and the results they've achieved — is one of the most effective arguments you can make.
Define the peer set carefully. "Over 500 hospitals use our product" is not benchmarking — it's a marketing claim. Effective benchmarking means comparing the target hospital against institutions that are genuinely similar: same bed count range, same teaching status, same geographic market, same patient acuity (measured by case mix index). A 200-bed community hospital in Ohio doesn't care that the Mayo Clinic uses your product. They care that three other 200-bed community hospitals in the Midwest use it and have measurable results.
Build the peer comparison with provider data. Use hospital databases to identify institutions that match the target on key dimensions. Then cross-reference with your customer list to identify which of those peers use your product. This gives you a specific, credible reference set: "Of the 14 hospitals in your state with 150-250 beds and a Level III trauma center, 6 currently use our system." That's a data point, not a marketing claim.
Quantify outcomes at peer institutions. Where possible, collect and present outcomes data from peer customers: complication rates, procedure times, length of stay, readmission rates, cost per case. Aggregate and anonymize if needed (some customers prefer not to be named). Peer outcome data directly addresses the committee's central question: "What will happen if we adopt this product?" If you can show that five comparable hospitals saw a 15% reduction in surgical site infections after switching to your product, the clinical case is strong.
Address regional and systemic factors. Some hospitals belong to the same GPO, share a regional market, or compete for the same physicians. These connections affect decision-making. If a hospital's main competitor just adopted your product, that creates urgency — the target hospital may want to match the capability. If the hospitals share a GPO, the pricing and contract terms are likely similar, which removes a potential objection. If they compete for the same surgical specialists, a physician who prefers your product at one hospital may push for it at the other.
Offer site visits to reference customers. The most powerful form of peer benchmarking is a site visit. If a VAC member can visit a comparable hospital, observe the product in use, and speak directly with the clinical team, that carries more weight than any slide deck. Coordinate with your reference customers to make these visits possible. Prepare both sides: brief your reference customer on what to highlight, and brief the visiting committee member on what to look for. A well-executed site visit often tips a borderline decision to approval.
Frequently Asked Questions
How long does the value analysis process typically take from submission to decision?
Most VAC evaluations take 3-6 months from initial submission to final decision. A straightforward supply conversion with strong clinical evidence and favorable pricing might clear in 60-90 days. A complex capital equipment decision involving clinical trials, multiple committee reviews, and financial modeling can take 6-12 months. Plan for a 4-month average and build this timeline into your sales forecast.
Can a vendor present directly to the value analysis committee?
Policies vary by institution. Some VACs invite vendors to present during a specific portion of the meeting. Others rely entirely on the submission package and the internal champion's presentation. A few prohibit vendor contact with VAC members entirely. Ask the supply chain contact about the committee's policy. Even when direct presentations are allowed, your champion's endorsement matters more than your pitch — prepare them thoroughly.
What is the most common reason VAC submissions fail?
Incomplete financial analysis. Committees routinely report that vendor submissions provide pricing data but lack total cost of ownership, implementation cost estimates, or reimbursement impact analysis. The second most common reason is insufficient clinical evidence — relying on a single study or manufacturer-sponsored data without independent validation. Address both comprehensively in your submission package.
How do value analysis committees handle physician-preferred items (PPIs)?
PPIs are one of the biggest challenges for VACs. Most committees have a formal PPI policy that allows physicians to request specific products but requires justification (typically clinical evidence that the preferred item produces measurably better outcomes than the standardized alternative). Some hospitals cap PPI exceptions at a percentage of total supply spend. As a vendor, if your product is the PPI, prepare evidence that supports the physician's preference. If your product is the standard and you're competing against a PPI request, provide evidence that outcomes are equivalent at a lower cost.
Related Resources
Get the Provider Data You Need
Tell us what you're looking for. We'll build a custom list matched to your target market.
Trusted by healthcare sales teams, medical device companies, and health IT vendors across the US.